Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:
As mentioned in an earlier KEI blog, on Thursday, March 19, a group of public interest groups met with the Obama administration’s trade officials. As a result of this meeting, USTR has promised to review its policies on transparency and invited groups to submit concrete proposals for evaluation. Further, these proposals are to be discussed as part of the review process in a follow up meeting next month.
Proposed areas of discussion include:
The following report was prepared by KEI, and reviewed by Daniel Sepulveda of USTR:
Call for More Reliable Costs Data on Clinical Trials James Love January 13, 1997Abstract The following is an article titled “Call for More Reliable Costs Data on Clinical Trials,” Published in the January 13, 1997 issue of the Marketletter, on… Continue Reading